[Skip to Content]
[Skip to Content Landing]
Views 1,817
Citations 0
Biotech Innovations
May 14, 2019

Off-the-Shelf Bioengineered Blood Vessels Tested in Trials

JAMA. 2019;321(18):1759. doi:10.1001/jama.2019.5806

Bioengineered blood vessels for hemodialysis access successfully supported blood flow and evolved into native-like blood vessels in patients with end-stage renal disease (ESRD) participating in 2 phase 2 trials, according to new findings published in Science Translational Medicine. The investigational human acellular vessels (HAVs), developed by Humacyte Inc, are also in phase 2 trials for peripheral arterial disease and vascular trauma.